Navigation Links
VIRxSYS to Host a Web Conference to Announce Clinical Trial Update
Date:7/21/2008

s, VIRxSYS has the most extensive data base of patient safety monitoring, in addition to being the largest manufacturer of clinical grade lentiviral vectors.

About VRX496

VRX496 is an investigational gene therapy for the treatment of HIV/AIDS. Current therapies for HIV-infected patients require daily drug regimens and have well documented side effects. It is anticipated that VRX496 will only require a minimal number of infusions and, to date, has been infused in 60 patients, which represents an accumulative time period of 110 therapy years. VRX496 also is different from previous gene therapies because it uses a lentiviral vector derived from HIV-1 itself. Unlike other viral vectors, lentiviral vectors appear to sustain expression of the delivered genes of interest for a longer period of time and do not appear to elicit an inflammatory immune response.

About VRX1023

VRX1023 is a preclinical investigational prophylactic HIV vaccine currently showing encouraging results in trials using small animals. Non-human primate studies are currently in progress. The objective of VRX1023 is to provide long-term immune protection against HIV replication, preventing the massive destruction of CD4 T cells and also halting the subsequent slow destruction of the immune system by HIV.

About VIRxSYS

VIRxSYS is a private biotechnology company using proprietary lentiviral vector delivery and RNA payload platforms to develop therapies for serious human diseases. The Company's initial lentiviral delivery technology was exclusively licensed from The Johns Hopkins University and has been substantially advanced in the Company's laboratories. The RNA payload technology was acquired and has been integrated with the Company's lentiviral delivery technology. In addition to preclinical programs for cardiovascular and genetics the Company is currently developing gene and vaccine therapies for HIV, one of which, VRX496, has advanced to Phase II human clinical
'/>"/>

SOURCE VIRxSYS Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. VIRxSYS Presents Data on HIV Vaccine at Keystone HIV Vaccine Symposia
2. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
3. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
4. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
5. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
6. ViroPharma to Present at Three Upcoming Healthcare Conferences
7. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
8. Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)
9. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
10. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
11. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...Nov. 20 Escalon Medical ...for its fiscal first quarter ended September 30, 2... product revenue decreased approximately $234,000,...iod ended September 30, 2009 as compared to the sa...the decreased net revenue of $8,434,000 compared w...
(Date:11/20/2009)...l., Nov. 20 /PRNewswire-FirstCall/ -- Landauer,...r the fiscal fourth quarter and full year of 2009 ... company will host a conference call for investors...n Time. Investors may access the live call by dial...ada), or 480-629-9835 (international callers), or ...
(Date:11/20/2009)...K, Nov. 20 Reportlinker.com announ... in its catalogue. ,, Pipettes & Pipettors....reportlinker.com/p0164373/Pipettes--Pipettors---A...ire&utm_medium=pr&utm_campaign=prnewswire ...ntegral part of any research laboratory. Large-sca...
Breaking Medicine Technology:Escalon(R) Reports First Quarter Fiscal 2010 Results 2Escalon(R) Reports First Quarter Fiscal 2010 Results 3Escalon(R) Reports First Quarter Fiscal 2010 Results 4Escalon(R) Reports First Quarter Fiscal 2010 Results 5Escalon(R) Reports First Quarter Fiscal 2010 Results 6Escalon(R) Reports First Quarter Fiscal 2010 Results 7Landauer, Inc. Sets Date and Time for Announcement of Fiscal Fourth Quarter and Full Year 2009 Results 2Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 2Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 3Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 4Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 5Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 6Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 7Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 8Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 9Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 10Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 11Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 12Economic Conditions Signal Long Term Shift in Rx Benefit Approach 57013 1Economic Conditions Signal Long Term Shift in Rx Benefit Approach 57013 2Economic Conditions Signal Long Term Shift in Rx Benefit Approach 57013 3Economic Conditions Signal Long Term Shift in Rx Benefit Approach 57013 4Caliper Life Sciences Launches IVIS 28R 29 In Vivo Imaging System with X Ray 14013 1Caliper Life Sciences Launches IVIS 28R 29 In Vivo Imaging System with X Ray 14013 2Caliper Life Sciences Launches IVIS 28R 29 In Vivo Imaging System with X Ray 14013 3Schering Plough Reports Long Term Vicriviroc Data From Phase II Open Label Extension Study in Treatment Experienced HIV Infected Patients 4990 1Schering Plough Reports Long Term Vicriviroc Data From Phase II Open Label Extension Study in Treatment Experienced HIV Infected Patients 4990 2Schering Plough Reports Long Term Vicriviroc Data From Phase II Open Label Extension Study in Treatment Experienced HIV Infected Patients 4990 3Schering Plough Reports Long Term Vicriviroc Data From Phase II Open Label Extension Study in Treatment Experienced HIV Infected Patients 4990 4Schering Plough Reports Long Term Vicriviroc Data From Phase II Open Label Extension Study in Treatment Experienced HIV Infected Patients 4990 5
...e Phase III ZODIAC study in advanced non-small cel...rug vandetanib, were presented today at the Americ...Orlando. Results show that the study met its prima...ndetanib to docetaxel resulted in a statistically ...al (PFS), the length of time a patient lives witho...
...hat Induction Chemotherapy prior to ChemoRadiother...ure in comparison to standard ChemoRadiotherapy al...ck Cancer Cooperative Group (TTCC) announced today...to standard ChemoRadiotherapy (CRT), a treatment p... upfront CRT alone, significantly prolonged Time-t...
Other Medicine Technology:Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology 2Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology 3Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology 4Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology 5Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer 2Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer 3
(Date:11/20/2009)..., , QUINCY, Mass., Nov. 20 Fo...upermarket Company removed from sale Shedd,s Count...i Rice and Shedd,s Country Crock ® Side Dishe...lfite allergen. ,, The following code dates an...® Side Dishes DELUXE Cheddar Broccoli Rice 21...
(Date:11/20/2009)..., , ST. LOUIS, Nov. 20 /PRNewswire-FirstCa...announced that it will present at the Bank of Amer...ld December 2-3, 2009, at the Crowne Plaza Hotel T...resent Wednesday, December 2nd at 8:30 a.m. Easter... access a live, audio webcast of Centene,s present...
(Date:11/20/2009)..., , NEW YORK, Nov. 20 /PRNewswire-FirstC...nnounced that it will broadcast Doctor Radio Re...rams , an in-depth special hosted by veteran journ...om.com/cgi-bin/prnh/20080819/NYTU044LOGO ) ,, ...Know About Mammograms will air November 21 live...
(Date:11/20/2009)...(Seattle, Washington) November 20, 2009Emergency m...s assess an estimated 350,000 cardiac arrests each...dden cardiac arrest survive. Better quality cardi...ital EMS providers may be associated with better p...tium (ROC) is the largest clinical research networ...
(Date:11/20/2009)...nadian study finds more severe cases than with sea...y News) -- Canadian researchers are reporting that...evere cases of H1N1 flu than seasonal flu. , "A...ctor for admission with pandemic H1N1 influenza, p...amples," wrote Dr. Upton Allen and fellow research...
Breaking Medicine News(10 mins):Health News:Stop & Shop Alerts Customers to Voluntary Recall by Unilever 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 3Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 4Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 5Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 3
...eveals patients at much greater risk for death , ...ent" heart attacks occur more often than previousl...premature death, according to a Duke University Me...don,t cause any pain and don,t leave behind tellta...
...ces absorption of rapamycin 3 to 4 times , ...t juice boosts the anti-cancer effects of the drug...ed 25 patients with advanced solid tumors, for whi...study, they also drank a glass (eight ounces) of g...
... Corporation (NYSE: SYK ) reported operating res...ws: , , First Quarter Highlights , , , , ...cy basis (2.0% decrease as reported) to $1,601 mil...sed 1.0% on a constant currency basis (5.3% decrea...
...vantages, limits of procedure, study suggests , ...-assisted surgery may be useful for removal of cer..., Their study included 36 patients with oral cavit...e margins (when no cancer cells are found at the e...
...ave a loved one take a look, study says , ... delivers a lifesaving message to older men about ...ma: If you can,t examine your own back, have a lov...it usually is thinner compared to a person finding...
... Medical Innovations, Inc. (NYSE: IMA ), a globa... their health at home through the merger of rapid ... that it will release its first quarter 2009 earni...ts and other corporate matters. During the confere...
Other Medicine News:Health News:'Silent' Heart Attacks More Common Than Thought 2Health News:Grapefruit Juice Boosts Anti-Cancer Drug's Effects 2Health News:Stryker Operating Results for Quarter Ended March 31, 2009 2Health News:Stryker Operating Results for Quarter Ended March 31, 2009 3Health News:Stryker Operating Results for Quarter Ended March 31, 2009 4Health News:Stryker Operating Results for Quarter Ended March 31, 2009 5Health News:Stryker Operating Results for Quarter Ended March 31, 2009 6Health News:Stryker Operating Results for Quarter Ended March 31, 2009 7Health News:Stryker Operating Results for Quarter Ended March 31, 2009 8Health News:Robotic Surgery Practical for Some Head, Neck Tumors 2Health News:Older Men Need to Take Closer Look for Melanomas 2Health News:Older Men Need to Take Closer Look for Melanomas 3Health News:Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET April 27, 2009 to Discuss First Quarter 2009 Results 2
...A nonabsorbable knitted product for use in hernior... flexible and compliant material that affords exce...ty, along with maximal porosity for necessary tiss...nstructed from polyethylene terephthalate, the sam...
...The 800 Series KTP/YAG Surgical Laser System is de..., dual-wavelength system designed for urology, gyn...l surgery, neurosurgery, pulmonary surgery and gas...lly cuts, vaporizes and coagulates tissue with min...
...The Gemini is the newest addition to Laserscopes f... distinct wavelengths to choose from, 1064nm Nd:YA...ding non-invasive aesthetic laser market by pushin...ness while maintaining the safety and reliability ...
...The Venus-i Laser System is a new, portable, light...pplications in dermatology, cosmetic and plastic s... ideal laser for skin resurfacing, it is the small...s on the market. It provides an ideal treatment fo...
Medicine Products: